AU765522B2 - Methods of treating tardive dyskinesia and other movement disorders - Google Patents

Methods of treating tardive dyskinesia and other movement disorders Download PDF

Info

Publication number
AU765522B2
AU765522B2 AU21041/99A AU2104199A AU765522B2 AU 765522 B2 AU765522 B2 AU 765522B2 AU 21041/99 A AU21041/99 A AU 21041/99A AU 2104199 A AU2104199 A AU 2104199A AU 765522 B2 AU765522 B2 AU 765522B2
Authority
AU
Australia
Prior art keywords
magnesium
nmda
memantine
composition
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU21041/99A
Other languages
English (en)
Other versions
AU2104199A (en
Inventor
Barry S. Fogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synchroneuron Inc
Original Assignee
Synchroneuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/006,641 external-priority patent/US5952389A/en
Priority claimed from US09/193,892 external-priority patent/US6294583B1/en
Priority claimed from US09/224,829 external-priority patent/US6057373A/en
Application filed by Synchroneuron Inc filed Critical Synchroneuron Inc
Publication of AU2104199A publication Critical patent/AU2104199A/en
Application granted granted Critical
Publication of AU765522B2 publication Critical patent/AU765522B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU21041/99A 1998-01-13 1999-01-13 Methods of treating tardive dyskinesia and other movement disorders Expired AU765522B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/006,641 US5952389A (en) 1998-01-13 1998-01-13 Methods of treating tardive dyskinesia and other movement disorders
US09/006641 1998-01-13
US09/193,892 US6294583B1 (en) 1998-01-13 1998-11-18 Methods of treating tardive dyskinesia and other movement disorders
US09/193892 1998-11-18
US09/224829 1999-01-04
US09/224,829 US6057373A (en) 1997-05-22 1999-01-04 Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
PCT/US1999/000144 WO1999036064A2 (en) 1998-01-13 1999-01-13 Methods of treating tardive dyskinesia and other movement disorders

Publications (2)

Publication Number Publication Date
AU2104199A AU2104199A (en) 1999-08-02
AU765522B2 true AU765522B2 (en) 2003-09-18

Family

ID=27358163

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21041/99A Expired AU765522B2 (en) 1998-01-13 1999-01-13 Methods of treating tardive dyskinesia and other movement disorders

Country Status (6)

Country Link
EP (1) EP1047436B1 (cg-RX-API-DMAC7.html)
JP (1) JP4562911B2 (cg-RX-API-DMAC7.html)
CN (1) CN1293573A (cg-RX-API-DMAC7.html)
AU (1) AU765522B2 (cg-RX-API-DMAC7.html)
CA (1) CA2318095C (cg-RX-API-DMAC7.html)
WO (1) WO1999036064A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2001008670A2 (en) * 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
AUPR625901A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A method for treatment and/or prophylaxis
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
WO2005110412A1 (en) * 2004-05-14 2005-11-24 Green Cross Corp. Neuroprotective properties of dextrorotatory morphinans
US20060079582A1 (en) * 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
AU2005309601A1 (en) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
EP1928445A1 (en) * 2005-09-16 2008-06-11 Cereuscience AB Method and means of preventing and treating sleep disordered breathing
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
HUE039750T2 (hu) * 2014-06-26 2019-02-28 Contera Pharma Aps Hidroxi-buspiron mozgászavarok kezelésére
CN104188970A (zh) * 2014-08-26 2014-12-10 上海交通大学医学院附属新华医院 右美沙芬在治疗眼睑痉挛或梅杰综合征中的应用
WO2017044491A1 (en) * 2015-09-08 2017-03-16 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
CN110430883A (zh) * 2017-02-10 2019-11-08 阿沙里那制药公司 用于医学治疗的3β-羟基-5α-孕烷-20-酮
CN111902138A (zh) * 2018-01-29 2020-11-06 法奈克斯公司 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗
WO2020229443A1 (fr) 2019-05-16 2020-11-19 Synapharm Industrial Synthesis Composé et composition pour utilisation dans le traitement du syndrome prémenstruel et/ou du trouble dysphorique prémenstruel
CN115184501A (zh) * 2022-07-20 2022-10-14 中国医学科学院病原生物学研究所 血清代谢物组合筛查在诊断肌张力障碍症中的应用
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4985256A (en) * 1988-04-27 1991-01-15 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5470978A (en) * 1992-11-18 1995-11-28 Eli Lilly And Company Process and intermediates for the preparation of excitatory amino acid receptor antagonists
MX9701477A (es) * 1994-09-02 1998-02-28 Univ Virginia Commonwealth Composicion para aliviar el dolor, que contiene un analgesico no narcotico y un mejorador de analgesia.
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDREASSEN ET.AL., BRIT.J.OF PHARMACOLOGY,119,'96.PP.751-757 *
METMAN ET.AL., AMINO ACIDS, 14(1-3), 1998, PP. 75-82 *
PAPA + CHASE, ANNALS OF NEUROLOGY, 39, 1996, PP. 574-578 *

Also Published As

Publication number Publication date
JP2002509104A (ja) 2002-03-26
CA2318095C (en) 2012-11-20
EP1047436B1 (en) 2009-10-21
AU2104199A (en) 1999-08-02
CA2318095A1 (en) 1999-07-22
CN1293573A (zh) 2001-05-02
EP1047436A2 (en) 2000-11-02
WO1999036064A3 (en) 1999-12-02
JP4562911B2 (ja) 2010-10-13
WO1999036064A2 (en) 1999-07-22

Similar Documents

Publication Publication Date Title
US7498361B2 (en) Methods of treating tardive dyskinesia and other movement disorders
US6057373A (en) Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
CA2318095C (en) Methods of treating tardive dyskinesia and other movement disorders
US5952389A (en) Methods of treating tardive dyskinesia and other movement disorders
US5866585A (en) Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6689816B2 (en) Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
Cohen et al. Clonidine ameliorates Gilles de la Tourette syndrome
DE69528773T2 (de) Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l-phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung
EP2729216A1 (en) Pharmaceutical composition for neurological disorders
CA2444269C (en) Treatment of disorders secondary to organic impairments
JPH03500411A (ja) コカイン中毒の処置および治療薬
AU2002258820A1 (en) Treatment of disorders secondary to organic impairments
US7255882B2 (en) Enkephalinase inhibitor and GABA precursor loading as anti-anxiety compositions
MXPA00006716A (en) Methods of treating tardive dyskinesia and other movement disorders
Sandyk Speech impairment in Parkinson's disease is improved by trancranial application of electromagnetic fields
MX2007012993A (es) Uso de moduladores de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes.
Vyas 28 Pharmacology of Behavioral Disorders
Sivakumar et al. Therapeutic benefits of phenibut–A review.
MXPA01009484A (es) Tratamiento de trastorno de estres post-traumatico, trastorno obsesivo-compulsivo y trastornos neuropsiquiatricos relacionados

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired